Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Jessica K Altman,Chezi Ganzel,Vamsi Kota,Bhavana Bhatnagar,Selina M Luger,Ashkan Emadi,Tsila Zuckerman,Stela Gengrinovitch,Gail J Roboz,Chen Blumberg,Jamie Koprivnikar,Michael Craig,Ofir Wolach,Olga Frankfurt,Liat Flaishon,Itai Levi,Ruth Ben Yakar,Anna Gourevitch,Shoshi Tessler,Jacob M Rowe,Mary-Beth M Percival ,James Mccloskey ,Darrel P Cohen ,Michael Keng ,Micah Burch ,Moshe Levy ,Dale Bixby

doi:10.1182/blood-2021-149361

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Jessica K Altman, Chezi Ganzel + Show 25 more

Open Access

https://doi.org/10.1182/blood-2021-149361

Copy DOI

#Research Funding #Speakers Bureau + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.